Learn More
BACKGROUND Apremilast works intracellularly to regulate inflammatory mediators. OBJECTIVE ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque(More)
BACKGROUND Three strategies are used to prevent relapse in patients with acute myeloid leukaemia in first remission. Most of those with suitable donors are offered allogeneic haemopoietic-stem-cell(More)
BACKGROUND Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. OBJECTIVES ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice(More)